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ABSTRACT  
The stability of the circadian rhythm for mammals depends on the levels of serotonin and 
melatonin, neurohormones that signal for lightness and darkness, respectively. Disruption in the 
stability of neurohormones has been shown to be a critical factor in psychopathological disorders 
in humans. For example, altering levels of melatonin in utero through administration of 
melatonin or the melatonin receptor antagonist, luzindole, has been shown to cause changes in 
developmental growth and adult behavior in the male rat. Analysis of relative adult hippocampal 
gene expression with RT-PCR revealed differences in ARNTL expression that suggested 
abnormality in clock gene expression of the rats that were prenatally exposed to altered levels of 
melatonin. Differences in the degree of plasticity as suggested by previous behavior testing did 
not result in differences in gene expression for GABA receptors or NMDA receptors. Morevoer, 
growth associated protein 43, GAP-43, a protein that is necessary for neuronal growth cones as 
well as long term learning has been found to be critical for axon and presynaptic terminal 
formation and retention in other studies, but hippocampal gene expression in our study showed 
no significant alteration after exposure to various maternal melatonin levels. However, ARNTL 
is a key regulatory component of clock genes and the circadian cycle so that alterations in the 
expression of thi critical gene may lead to critical changes in neuronal growth and plasticity. Our 
data support the conclusion that the manipulation of maternal melatonin levels alters the brain 
development and the circadian cycles that may lead to physiological and behavioral 
abnormalities in adult offspring. 
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INTRODUCTION 
The Circadian Rhythm in Mammals 
The circadian rhythm in mammals is the daily behavioral rhythm that is primarily 
controlled by the fluctuating levels of serotonin and melatonin. Disruption in the stability of 
these two neurohormones is one of the critical factors in psychopathological disorders in 
humans. For instance, changes in melatonin levels have been shown in schizophrenia (Rao et al., 
1994), and depression (Kennedy et al., 1989) as well as other mood disorders (Srinivasan et al., 
2006). It is known that melatonin is a key player in maintaining a healthy daily rhythm; however, 
it is not clear how abnormal fluctuations of this neurohormone influence the brain and relate to 
brain-related diseases.  
 Melatonin is synthesized from serotonin and secreted by the pineal gland during the dark 
period of the light-dark cycle under normal environmental conditions (Cardinali and Pevet, 
1998). It is produced via a multi-step pathway beginning with the synthesis of 5-
hydroxytryptophan from tryptophan via tryptophan hydroxylase. The 5-hydroxytryptophan is 
converted to serotonin by aromatic amino acid decarboxylase and the acetylation of serotonin by 
arylalkylamine N-acetyltransferase results in N-acetylserotonin. The final step involves 
hydroxyindole-O-methyltransferase which converts N-acetylserotonin to melatonin (Simonneuax 
et al., 2003).  The synthetic melatonin receptor antagonist, luzindole, has a structure that is very 
similar to melatonin but with an additional benzyl group. This compound has been shown to 
competitively antagonize the melatonin receptors at a presynaptic level (Dubocovich., 1988). 
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Figure 1: Simplified diagram of the circadian rhythm monitored by suprachiasmatic 
nucleus (adapted from Drake, 2010). Light induces retinal ganglion cells to signal to the 
suprachiasmatic nucleus along the retinohypothalamic tract. The suprachaiasmatic nucleus, 
which contains the primary circadian molecular clock processes inputs from the retinal ganglion 
cells as well as other brain regions and elicits the release of melatonin by the pineal gland on top 
of outputs to other brain regions. Melatonin is then released into the cerebrospinal fluid and 
blood, spiking in levels at night.   
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Figure 2: Diagram of melatonin synthesis (a) (adapted from Koch et al., 2009) and 
molecular diagram of melatonin receptor antagonist, luzindole (b). Within the pineal gland, 
5-hydroxytryptophan is synthesized from tryptophan by tryptophan hydroxylase. 5-HTP 
decarboxylase transforms 5-HTP into 5-HT, or serotonin. Acetylation of serotonin by 
arylalkylamine N-acetyltransferase produces N-acetylserotonin. Melatonin is produced from N-
acetylserotonin by hydroxyindole-O-methyltransferase.  
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(a) 
  
 
 (b)  
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The secretion of melatonin is controlled by the circadian clock within the suprachiasmatic 
nuclei (SCN) and is entrained to a light-dark cycle that is roughly 24 hours long (Claustrat et al., 
2005). SCN activity is responsive to the amount of light from the environment via signals from 
the retinal ganglion cells that project through the optic chiasm and onto the SCN. The SCN then 
projects indirectly to the pineal gland, where it is able to control the nightly secretion of 
melatonin. Cells in the SCN are also capable of responding to the pineal gland’s melatonin 
secretion via melatonin receptors. Hence, SCN control of melatonin secretion occurs through a 
feedback loop that consists primarily of inputs from the retinal ganglion cells, but also from 
endogenous melatonin secreted from the pineal and acting back on the SCN.  
 
Clock Genes 
Within the SCN, a circadian rhythm is generated by the oscillations in various regulatory 
protein levels. Brain and muscle aryl hydrocarbon receptor translocator (ARNT)-like (BMAL1) 
and Circadian Locomotor Output Cycle Kaput (CLOCK) form a heterodimer that binds to E-
boxes which are regulatory sites within the sequence of DNA that allows the expression of 
Period (PER) and Cryptochrome (CRY) mRNA as well as other clock controlled genes. PER and 
CRY protein form a dimer (PER/CRY), which then feedback to inhibit the BMAL1/CLOCK 
dimer function (Okamura et al., 2002). Furthermore, inhibition of the BMAL1/CLOCK cycle is 
also conducted by a protein known as nuclear receptor subfamily 1, group D, member 1 
(NR1D1). NR1D1 works by indirectly inhibiting the expression of the BMAL1 gene by blocking 
its transcription, thereby decreasing the amount of BMAL1 protein (Layeghifard et al., 2008).  
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Figure 3: Simplified model of clock gene network in the suprachiasmatic nucles of 
mammals (adapted from Richter et al., 2004). BMAL1/CLOCK heterodimer binds to E-boxes 
on the DNA transcribing clock genes and clock controlled genes. Clock genes, PER1 and CRY 
form a dimer that then blocks BMAL1/CLOCK from binding to the E-box, thereby inhibiting 
transcription of the clock genes and clock controlled genes. 
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Figure 4: Simplified model of clock gene network in the suprachiasmatic nucles of 
mammals in relation to NR1D1’s inhibitory effects on BMAL1 (adapted from Sukumaran 
et al., 2010). NR1D1, noted as REVERB in diagram, has inhibitory effects on the transcription 
of BMAL. High levels of REVERB will inhibit the transcription of BMAL, thereby decreasing 
the possibility of forming a BMAL/CLOCK heterodimer, affecting the level or protein 
production. 
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The fluctuating concentration differences of the BMAL1/CLOCK dimer in relation to the 
PER1/CRY dimer created by the activation and repression of downstream gene targets are what 
create circadian rhythm within the SCN.  
 
Melatonin and the Circadian Rhythm 
There are two main hypotheses of how melatonin peaks are positively correlated with the 
length of the dark phase during the light-dark cycle. In what is known as the “duration 
hypothesis”, the duration of the nocturnal melatonin peak is considered to be the critical 
parameter in understanding the light phase of the light-dark cycle (Cardinali and Pevet, 1993). In 
contrast, the “coincidence hypothesis”, states that circadian variation of sensitivity to melatonin 
is involved with the light response. When intact Syrian hamsters were kept at long photoperiods 
and administered exogenous melatonin, their circadian response modeled those that were kept at 
normal photoperiods, indicating that the exogenous melatonin advanced the circadian sensitive 
phase (Stetson and Watson-Whitmyre, 1985). It is unclear whether or not either of these 
hypotheses is an accurate explanation for SCN interaction with the photoperiods and regulation 
of melatonin levels; however, both hypotheses underline the ties between the SCN, photoperiods 
cued by the retinal ganglion cells, and the melatonin that is released from the pineal gland. 
 In addition to its association with the daily behavioral rhythm, melatonin is also known to 
be a regulator of various bodily functions that oscillate with the daily cycle of light and dark. For 
instance, core body temperature in humans, which exhibits a maximum during the day and a 
minimum at night, has been shown to be coupled with the sleep-wake cycle in normal conditions 
(Cagnacci et al., 1992). Experiments have also been conducted for those suffering from insomnia 
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or circadian rhythm disorders and the data show that low-dose melatonin treatments promoted 
regulation in sleep onset and sleep maintenance without disrupting other functions associated 
with circadian rhythm (Zhdanova and Tucci., 2003; Sack et al., 1998). It is clear that melatonin 
is a key player in the regulation of the circadian rhythm and multiple physiological functions. In 
fact, evidence suggests that alternations in melatonin regulation may increase the risk for mood 
disorders and cognitive dysfunction (Kripke et al., 2009). One study showed that depressed 
patients exhibited clear circadian rhythm abnormalities that consisted mainly of melatonin 
amplitude reduction at night (Souetre et al., 1988). In addition, differences in photoperiods and 
the respective levels of melatonin were compared across generations in a maternal-fetal 
chronobiological study. This investigation found that reduced melatonin concentrations impaired 
in the animal’s ability to regulate internal temperature and had detrimental effects on immature 
hippocampal neurons in animals (Schwartz, 2011). 
 
NMDA Receptors 
 Mounting evidence suggests that detrimental effects of altered melatonin levels occur 
when circadian rhythms are disturbed. For example, schizophrenic patients, who have altered 
melatonin levels, also show impairments in memory and learning. Many of these changes have 
been correlated with changes in key proteins that mediate synaptic function. For example, levels 
of key postsynaptic receptors, subunits of a major glutamate receptor, the n-methyl-D-asparate 
(NMDA) receptor, have been shown to be differentially expressed in schizophrenic patients with 
right/left hemisphere differences (Vrajova et al., 2010).  Studies show that melatonin alters 
NMDA subunit concentrations in a dose-dependent manner leading to the possibility that the 
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differences in concentration of NMDA subunits are linked to the alterations in NMDA receptor 
function (Sutcu et al., 2006). Since these receptors are key mediators of learning and memory, 
abnormalities in these functions are likely candidates for disturbances linked to mood disorder 
and schizophrenia. 
 
GABA Receptors 
 Additional synaptic disturbances have been associated with other major synaptic 
receptors. For example, in contrast to glutamate’s excitatory role, the neurotransmitter gamma-
aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the mammalian central 
nervous system. GABA receptors can be broken down into two groups of receptors, ionotropic 
(GABAA) and metabotropic (GABAB), and these receptors have been shown to influence 
circadian rhythm, primarily through regulation of cell activation or inactivation, and to contribute 
to jet-lag symptoms and phase-shifting (Golombek et al., 1996). With regard to the clock genes, 
the effects of GABA on individual clock cells have been studied with results indicating that 
GABA acting through its type A receptors is involved in phase shifting and synchronization of 
clock cells (Liu and Reppert, 2000). Although the interactions between GABA and other 
neurotransmitters in mood disorders such as schizophrenia are not entirely understood, 
abnormalities in GABA interactions are associated with schizophrenia (Wasserf et al., 2003). It 
has also been shown that GABAergic projection from the SCN to the dorsomedial hypothalamus 
controls the release of melatonin during the dark phase (Kalsbeek et al., 1996). It is possible that 
changes in melatonin levels may be coupled to the altered levels of GABA in schizophrenia. 
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 In summary, the synthesis and release of melatonin during prenatal development, a period 
of time when circadian rhythms are being established, is central to an individual’s health. 
Moreover, accurate regulation of melatonin levels is also critical during postnatal development. 
This is especially true in the hippocampus, a brain region where acquisition and consolidation of 
learning and memory take place.  Hippocampal lesions have been used to demonstrate the 
importance of the hippocampus for short-term and temporal memories in humans (Scoville and 
Milner, 1957). In addition, hippocampal lesions result in behavioral disinhibition and reduced 
anxiety (Bannerman et al., 2004). An altered synaptic circuitry within the hippocampus and its 
extrinsic connections has also been associated with aberrant functional connectivity in 
schizophrenic individuals (Harrison, 2004). These observations suggest that melatonin may 
regulate neuronal plasticity (El-Sherif et al., 2003) and cell survival of new neurons (Ramirez-
Rodriguez et al., 2009), which are required for hippocampal and cognitive function in adult rats.  
 
Hypothesis 
 Altering maternal melatonin levels via exogenous melatonin treatment during pregnancy 
leads to differential mRNA gene expression in adult offspring for gene products mediating the 
proper control of the circadian rhythm. 
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MATERIALS AND METHODS 
Animals and Tissue Collection 
Eleven pregnant Sprague-Dawley dams from Hilltop Laboratories were randomly 
assigned to three treatment groups. The control group was injected with a vehicle containing 
50%(volume/volume) sterile, filtered DMSO (Sigma Aldrich, St. Louis, MO) in distilled water. 
The melatonin group was injected with 5mg/kg melatonin (N-acetyl-5-methoxytryptamine) 
(Sigma Aldrich). The luzindole group was injected with 5mg/kg luzindole (N-acetyl-2-
benzyltryptamine) (BA Chemicals, London, UK), a nonselective melatonin receptor antagonist 
(Dubocovich, 1998). All drugs were administered subcutaneously at a volume of 0.05 to 0.06mL 
prior to the dark cycle at 1600 to 1800 for 5 days from days 14 to 18 of gestation. Dams were 
housed individually, given food and water ad libitum and kept at a controlled temperature of 
23°C under a strict 12hour light-dark cycle.  
Offspring were weighed at birth, and on postnatal day 21, male offspring from the same 
treatment group were housed in pairs. Every 5 to 7 days, body mass per rat and food intake per 
cage were measured from weaning to sacrifice. After 120 days, half of the animals were 
sacrificed at 0000 hours and the rest were sacrificed at 1200 hours. Right and left hippocampi 
were dissected from each brain. (All animal protocols used were in accordance with the NIH 
Guide for Care and Use of Laboratory Animals and reviewed and approved by the Animal Care 
and Use Committee of Bucknell University).  
Prior to reverse transcription, total RNA was extracted from the hippocampus of 
individual 120-day old male rats and purified using TRIzol (Invitrogen, Carlsbad, CA).  Total 
RNA was then reverse transcribed using a RETROscript kit (Ambion, Austin, TX). Primers were 
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designed with the online NCBI database and confirmed with BLAST and then ordered from 
MWG Oligo Synthesis (High Point, NC). Real-time PCR was performed in 96-well optical 
plates with 0.05µM of forward and reverse primers, cDNA from 2µg  RNA input (diluted 1:50) 
and 12.5µL Supermix (Bio-Rad, Hercules, CA). The assay was conducted using the iCycler iQ 
Real Time PCR Detection System (Bio-Rad, Hercules, CA).  
 
Primer Design, RT-PCR and Analysis 
Efficiency of the primers was determined using a serial dilution of  RT-PCR products. 
Efficiencies were calculated using the following formula: 
 
 
 
Prior to analyzing experimental plates, control plates for each primer pair were analyzed 
by testing randomly selected samples, samples not containing cDNA, or dH2O. Primer pairs that 
showed a high efficiency of amplification and “clean” control plates were then run on gel 
electrophoresis with 12% Boraid to ensure that there was no DNA contamination. Clean controls 
are defined such that: randomly selected samples, samples not containing cDNA, and samples 
with dH2O only did not display a fluorescence peak before 35 cycles. Final genes of interest 
were selected only when the two criteria 1) clean controls confirmed by gel electrophoresis and 
2) high efficiencies were met. RT-PCR on samples were conducted using a thermocycling 
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program of 3’ at 95⁰C, 40x15’’ PCR cycles at 95⁰C, 1’ at 60⁰C , 1’ at 55⁰C and concluded with 
80x15’’ with a temperature ramp of 0.5⁰C/repeat where dissociation curve data were collected to 
ensure that only target sequences were amplified. 
The following genes were amplified from the hippocampus-derived cDNA: glutamate N-
methyl-D-aspartate receptor (GRIN) subunits (GRIN1, GRIN2A, GRIN2B), gamma-
aminobutyric acid (GABA) A receptor 2-2 (GABAA2-2), gamma-aminobutyric acid (GABA) B 
receptor 1 (GABAB1), growth associated protein 43 (GAP43), neural cell adhesion molecule 1 
(NCAM1), aryl hydrocarbon receptor nuclear translocator-like (ARNTL) and nuclear receptor 
subfamily 1 member 1 (NR1D1). Each gene was co-amplified with succinate dehydrogenase 
complex subunit A (SDHA), a housekeeping gene to control for any pipetting errors. 
Two negative controls were conducted to ensure that there was no contamination in both 
primers and samples. RT-PCR was conducted for each primer pair where cDNA samples were 
substituted with dH2O to verify that there was no DNA contamination with the primers. 
Additionally, gel electrophoresis was conducted to reconfirm the lack of DNA contamination in 
the primers. RT-PCR was also conducted for each primer pair where cDNA was substituted with 
RNA to verify no DNA contamination of the primer samples.  Efficiencies for each primer pair 
were conducted for those primer pairs with clear negative controls. 
 Triplicates of each sample were run and assigned cycle threshold (CT) values. 
Differences in CT (dCT ) were determined by subtracting the CT SDHA from CT  for the genes of 
interest. The treatment/time group with the highest dCT was set to zero and the dCT  for each 
group was subtracted from the group with the highest dCT  which was used to calibrate the others 
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(ddCT ). The ddCT  values were calculated as powers of 2 (2^ ddCT ) to account for exponential 
doubling during PCR and to provide a relative measure of gene expression for each gene. 
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Table 1: Primer Sequences used in real-time PCR (NCBI) 
Primer ID Primer Sequence 5’-3’ Accession No. Length, nt 
SDHA Fwd: CGGGGTTGGCGCAGTTTCGA 
Rev: AAGTGAAAGCCACGAGTCGCCC 
NM130428.1 134 
GRIN1 Fwd: CTGCTGGACCGCTTCAGTCCC 
Rev: CCGGAGTTGAGCAGGACGCC 
NM017010.1 93 
GRIN2A Fwd: TCAGTGCCTCCGTCTGGGTGA 
Rev: GCCCGTGGGGAGCTTCCCT 
NM012573.3 113 
GRIN2B Fwd: ATGCAAGCGAGAAGAGGACCCTGG 
Rev: CTTCAGCTAGTCGGCTCTCTTGGT 
NM012574.1 94 
GABAA2-2 Fwd: GTGGAACCCAGCCAGGTTGGTG 
Rev: GCTGTCTCCCAGTCCTGGTCTAAGA 
NM001135779.1 136 
GABAB1 Fwd: GCCCCACTGCCAGGTGAATCG 
Rev: GCCCCCGCTCATGGGAAACA 
NM031028.3 82 
GAP43 Fwd: CCAAGCTGAGGAGGAGAAAGAAGCT 
Rev: GGGGCAACGTGGAAAGCCGT 
NM017915.3 136 
NCAM1  Fwd: CCAGCGCACCCAAGCTGGAA 
Rev: TCGGAGGCGAGCGCTCTGTA 
NM031521.1 130 
ARNTL Fwd: GAGCGGTTTGCCAGTCGGA 
Rev: CCGTCGCCGCCGCTCTATTT 
NM024362.2 94 
NR1D1 Fwd: CATTGCCCACGGGGCGAGAG 
Rev: ACACCACCTGTGTTGTTGTTGGAGT 
NM001113422.1 124 
Final concentration of each primer was 1µM 
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RESULTS 
 
Effects of Altered Prenatal Melatonin Signaling on Litter Size, Litter Composition, Growth 
and Feeding Patterns 
 The difference in effects of administration of vehicle, 5mg/kg melatonin, or 5mg/kg 
luzindole to pregnant dams from days 14-18 of gestation on litter size and birth male body mass 
were not significant (Table 2). Despite the lack of significance, the effect of treatment on litter 
size was approaching significance for a decrease in litter size for melatonin-treated dams 
compared to luzindole-treated dams, both in respect to the litter size for control dams (P=0.060 
for melatonin, P=0.0805 for luzindole).  
 Body mass and food intake were monitored for male rat litters treated prenatally with 
vehicle, melatonin, or luzindole (Figure 5). The body mass curve for litters treated prenatally 
with melatonin was significantly increased from those treated prenatally with vehicle or 
luzindole (P=0.00171 for reduced control and melatonin model to full control and melatonin 
model, P=.01084 for reduced melatonin and luzindole model to full melatonin and luzindole 
model, where growth data over time was averaged by litter, and linear regression analysis was 
performed by comparison of full and reduced models for body mass and food intake by treatment 
with family-wise Bonferroni correction). No significant effect on food intake was found in 
response to prenatal treatment.  
 In addition, prenatal treatment did not have significant impact on percentage of body fat, 
left hippocampus mass, right hippocampus mass or left hippocampus mass to right hippocampus 
mass ratio. 
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Table 2: Litter size and average mass of male pups per litter for dams treated with vehicle 
(CON), 5mg/kg melatonin (MEL) or 5mg/kg Luzindole (LUZ) during days 14-18 of 
gestation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Litter size 
(Pups) 
Average Male Mass 
(g/pup per litter) 
Control (CON) 14.3 ± 0.9 12.7 ± 1.0 
Melatonin (MEL) 11.8 ± 0.6 13.5 ± 0.9 
Luzindole (LUZ) 14.8 ± 0.9 11.8 ± 1.5 
   
CON-MEL-LUZ P=0.060 P=0.618 
CON-MEL P=0.197 P=1.00 
CON-LUZ P=1.00 P=1.00 
MEL-LUZ P=0.085 P=1.00 
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Figure 5. Average body weights and food intake of male rats from dams treated with 
vehicle, melatonin, or luzindole. Average body mass (a) and food intake (c) of 11 litters 
(Control n=3, Melatonin n=4, Luzindole n=3) measured from postnatal day (PD) 21 to PD 120. 
Litters treated with prenatal melatonin were found to have body mass curves significantly 
different from controls and Luzindole treated litters, (**P<0.01, *P<0.05) respectively. No 
significant effect of prenatal treatment on food intake was found. 
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Table 3: Percent body fat, left and right hippocampus mass, and ratio of left hippocampus 
mass to right hippocampus mass at sacrifice for male rats from dams treated with vehicle, 
melatonin and luzindole. 
 
 
 
 
 
 
 
 
 
 
 
 Percent Body 
Fat (fat/body 
mass) 
Left 
Hippocampus 
Mass (mg) 
Right 
Hippocampus 
Mass (mg) 
Left Hippocampus/ 
Right Hippocampus 
Mass 
Control (CON) 3.54 ± 0.16 75 ± 3 74.8 ± 1.8 1.01 ± 0.04 
Melatonin (MEL) 3.4 ± 0.3 76 ± 3 75 ± 2 1.03 ± 0.03 
Luzindole (LUZ) 3.46 ± 0.14 72.4 ± 1.3 72.8 ± 1.5 1.01 ± 0.03 
     
CON-MEL-LUZ P=0.855 P=0.411 P=0.651 P=0.901 
CON-MEL P=1.00 P=1.00 P=1.00 P=1.00 
CON-LUZ P=1.00 P=1.00 P=1.00 P=1.00 
MEL-LUZ P=1.00 P=0.606 P=1.00 P=1.00 
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Effects of Altered Prenatal Melatonin Signaling on Hippocampal Gene Expression 
 Primers of targeted genes were tested for DNA contamination by running RT-PCR using 
selected cDNA samples, DNA-free samples, and dH2O substituted for normal samples. Gel 
electrophoresis was conducted to insure the clarity of chosen primers (Figure 6). Primers that 
showed clarity by having single bands appear only on the RT+ lanes were then tested and 
efficiency was calculated using a small dilution of selected samples (Figure 7, Table 4). Nine 
primers with the highest efficiencies were chosen to be tested on experimental samples. 
 Hippocampal gene expression in the hippocampi of male rats prenatally treated with 
vehicle, melatonin and luzindole were analyzed (Figure 8, Figure 9). Analysis of gene expression 
between sides of the hippocampus (right vs. left) within two distinct time periods (noon vs. 
midnight) failed to produce significant difference in circadian expression (data not shown). 
Analysis of gene expression between two distinct time periods (noon vs. midnight) showed close 
to significant differences for the ARNTL gene (P=.09 for control vs. melatonin at noon and 
P=0.088 for noon vs. midnight for control group). Trends were observed in other genes albeit 
there was no significant difference amongst the groups or times for all genes, altered melatonin 
levels, whether they were increased with additional melatonin or decreased with luzindole 
administration. 
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Figure 6: Representative gel image photographed after gel electrophoresis was performed. 
a) Gel 1: 1) Ladder; 2) GRIN1A RT-; 3) GRIN1A RT+; 4) GRIN 1A S-; 5) GRIN2A RT-; 6) 
GRIN2A RT+; 7) GRIN2A S-; 8)GRIN2B RT-; 9)GRIN2B RT+; 10) GRIN2B S-; b). Gel 2: 1) 
SDHA S-; 2)SDHA RT+; 3)SDHA RT-; 4)GAP43 S-; 5)GAP43 RT+; 6)GAP43 RT-; 7) Ladder. 
RT- denotes DNA-free samples, RT+ denotes cDNA samples and S- denotes dH2O samples. 
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(a) 
 
 
 
(b) 
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Figure 7. Representative Efficiency Curve.* Efficiency curves were determined through a 
serial dilution of selected samples that were run using the RT-PCR mix.  Efficiency was 
calculated raising 10 by the negative reciprocal of the slope. *SDHA primer efficiency is 
displayed. 
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Table 4: Efficiencies of primers. 
 
 
 
 
 
 
 
 
Gene Intercept Slope R2 Efficiency 
ARNTL 33.724 -3.5614 0.98942 1.77 
NR1D1 33.978 -3.6019 0.97755 1.78 
GRIN1 29.047 -3.4022 0.9817 1.97 
GRIN2A 31.442 -4.2103 0.9968 1.73 
GRIN2B 30.576 -3.9476 0.9958 1.79 
GABAA 32.0489 -4.8930 0.9670 1.60 
GABAB 33.969 -4.1727 0.9971 1.74 
GAP43 30.629 -4.1484 0.9834 1.74 
NCAM 29.007 -3.5194 0.99381 1.95 
SDHA 29.889 -3.4286 0.9957 1.96 
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Figure 8. The effects of prenatal melatonin or luzindole on adult male rat hippocampal 
gene expression. Relative cycle number of fluorescence for hippocampal cDNA during RT-PCR 
with primers for GRIN1, GRIN2A, GRIN2B (a); GABAA, GABAB, GAP43 (b); NCAM1, 
ARNTL, NR1D1 (c). 
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(a) 
 
 
(b) 
 
(c) 
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Figure 9. Relative gene expression of ARNTL (a), NR1D1V (b), GRIN1 (c), GRIN2A (d), 
GRIN2B(e), GABAA (f), GABAB (g), GAP43 (h), and NCAM1-1 (i), in hippocampal tissues 
from adult male rats exposed to melatonin or luzindole in utero compared to controls. 
Animals were sacrificed at noon or midnight. Values are expressed in relative expression with 
the group expressing the lowest level of each target gene evaluated set to 1.  
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(a) 
 
 
 
 
 
 
 
 
 
 
 
*P<0.1compared to Control at Noon. †no significant difference between Control at noon, 
Luzindole at noon and Luzindole at midnight. 
(b) 
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(c) 
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(e) 
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(g) 
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(i) 
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DISCUSSION 
This study was designed to test the effects of altered maternal melatonin levels on 
hippocampal gene expression in adult male rat offspring. Existing research in this field is very 
limited, however, we are adding our data to the literature and were able to develop an 
explanation for our observations. 
 
Melatonin and the Hippocampus 
Melatonin has two main receptors MT1 and MT2, both of which have been found in 
various regions within the hippocampus, including the dentate gyrus, CA3 and CA1 regions 
(Musshoff et al., 2002). In a previous study conducted by my fellow student, Joshua Ripple, 
behavior experiments including the open field test, Morris water maze, and elevated plus maze 
were conducted. Rats that were exposed to higher prenatal melatonin levels showed increase in 
rearing in the open field test and an increased right turn preference in the elevated plus maze. On 
the other hand, rats exposed to prenatal luzindole displayed greater freezing and grooming 
behavior in the open field test and improved learning in the Morris water maze. Using the same 
samples used in this study, gene expression for both melatonin receptors was measured in a 
similar fashion using rt-PCR. For the offspring whose mother received the exogenous melatonin, 
MT1 gene expression was significantly higher than in the control and luzindole group. In 
addition, MT1 gene expression was significantly higher compared to MT2 gene expression for all 
three experimental groups (Ripple, 2010). The alterations in circadian rhythm may, in part, be 
explained by this increase in MT1 gene expression associated with the increased melatonin levels 
and ARNTL gene expression found in our study. 
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 Melatonin has also been studied as a contributor to learning, memory, and 
psychopathological disorders that depend on neuronal plasticity processes in the hippocmpus. 
Alterations in melatonin receptor concentration have been observed in various 
psychopathologies. For instance in Alzheimer’s disease (AD), a significant increase in MT1 
receptors have been found, possibly as a regulatory response to the impaired melatonin levels in 
AD individuals (Savaskan et al., 2001). Additionally, MT2 receptors are significantly decreased 
in AD patients, suggesting that MT2 receptors are mediated by melatonin in the hippocampi of 
humans (Savaskan et al., 2005). Such findings have led to possible therapeutic approaches that 
involve supplementing antidepressant treatment with some type of melatonin receptor agonist. It 
is thought that the ratio of MT1/MT2 receptors may contribute to improving antidepressant effects 
(Hirsch-Rodriguez et al., 2007). 
 Unlike MT1, MT2 receptors have been shown to have inhibitory effects on long-term 
potentiation (LTP) using the elevated plus-maze as observed in mice where inhibitory actions of 
melatonin were lost in those deficient in MT2 but not in MT1 (Larson et al., 2006). Furthermore, 
administration of luzindole was seen to prevent the inhibition of LTP by melatonin via the MT2 
receptors (Wang et al., 2005). However, melatonin’s inhibitory characteristics were not seen in 
the MT1 receptors thereby suggesting opposing receptor activity for the two melatonin receptors 
(Musshoff et al., 2002). 
 Previously, it was found that the lasting effects of overexpressed melatonin levels in 
utero show an increase in MT1 receptors but not in MT2 receptors; thus the increased melatonin 
receptor ratio is similar to that shown in AD individuals. In addition, it has been shown that 
altered maternal melatonin levels significantly affect brain function in offspring. For example, at 
postnatal day 9, offspring of pinealectomized Wistar rat dams had reduced melatonin receptor 
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gene expression in their brains (Zitouni et al., 1995). In addition, exogenous melatonin 
administration in pinealectomized Swiss albino rats showed inhibition of harmful effects of 
epilepsy, thereby allowing proper hippocampal development in the offspring (Turgut et al., 
2006).  
Melatonin and Clock Gene Expression 
In addition to the melatonin receptors, the aryl hydrocarbon receptor nuclear translocator-
like (ARNTL) gene in the rat contributes to circadian rhythm generation. This gene is considered 
to be an ortholog to the brain and muscle aryl hydrocarbon receptor nuclear translocator 1 
(BMAL1) protein in humans, which forms a heterodimer with the circadian locomotor output 
cycles kaput (CLOCK) protein. The BMAL1/CLOCK heterodimer then is a critical regulatory 
component since it binds to a promotor region, the E-box, which allows for the transcription of 
many genes including those associated with circadian rhythm, the period (PER) and 
cryptochrome (CRY) genes (Gekakis et al., 1998; Sangoram et al., 1998). PER and CRY, in their 
protein form, also form a dimer. PER is known to be a positive regulator of the circadian loop, 
but CRY is known to be a negative regulator (Shearmen et al., 2000). Hence, the increase in 
CRY concentration would lead to an inhibition of the BMAL1/CLOCK dimer, which then 
decreases the rate of transcription of PER and CRY. As PER/CRY protein levels increase, they 
form a dimer that exerts negative feedback in this loop. When concentrations of PER and CRY 
are low, BMAL1/CLOCK form a dimer to allow transcription. This fluctuation of protein 
production creates the circadian rhythm within the SCN. 
Irregularities in the oscillation of clock gene expression lead to arrhythmic circadian 
systems that have been associated with physiological dysfunction. For example, synchronized 
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circadian cycle was absent in Wistar rats following a 30-day exposure to continuous light. This 
disruption was especially apparent for BMAL1, which was no longer expressed in synchrony 
with other clock genes (Novakova et al, 2011). Moreover, low amplitude PER gene expression 
was observed using in situ hybridization and was associated with the lack of intercellular 
synchrony, which is critical for generating circadian rhythm. In our study, the high BMAL1 
expression detected in the offspring from treated dams exposed to melatonin at noon may 
increase the risk of arrhythmic circadian cycles, as the BMAL1 expression at noon did not differ 
from the BMAL1 expression at midnight in these animals. In contrast, the offspring from control 
rats exhibited a significantly higher expression of BMAL1 at midnight. In contrast to both of 
these groups, Luzindole decreased the expression of BMAL1 at both time points.  
Our finding is interesting considering that melatonin is an important regulator of 
rhythmic clock gene expression in mice. For example, loss of melatonin receptors and the effect 
this loss had on clock gene expression was studied using melatonin 1-receptor knockout and 
melatonin 2-receptor knockout mice (Von Gall, 2005). Using in situ hybridization and western 
blotting, gene expression was analyzed in the hypophyseal pars tuberalis, one of the main target 
regions for melatonin. In this study, they found that gene expression of PER1, CRY1, CLOCK 
and BMAL1 were dramatically reduced only in the melatonin 1-receptor knockout mice. This 
indicates that melatonin, through its melatonin 1-receptor, has regulatory effects on critical clock 
genes such as PER and CRY, and most likely BMAL1, thereby playing a crucial role in 
regulating and maintaining circadian rhythm.  
Another study that directly relates to our study is one in which maternal melatonin levels 
were manipulated in pregnant Capucin monkeys. Suppression of maternal melatonin and 
addition of maternal melatonin resulted in offspring that exhibited lowered clock gene expression 
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in the fetal SCN (Torres Farfan et al., 2006). Hence, altering melatonin levels in utero has 
significant effects on circadian rhythm development and clock gene expression, which include 
the expression of BMAL1, PER2, CRY2 and CLOCK. Since fetuses rely on their mother’s 
hormonal levels to establish bodily functions like circadian rhythm and endocrine modulation 
(Tamura et al., 2008), altering the melatonin levels during gestation can lead to critical changes 
in the fetal clock gene expression. 
 The full consequences of altered fetal clock gene expression and changes in circadian 
rhythms are unknown. However, it is known that BMAL1 and PER proteins have other 
properties apart from their function as the circadian oscillator. For example, they participate in 
essential non-redundant regulatory roles during tissue homeostasis and aging (Kondratov, 2007). 
Not only is there a loss of circadian rhythm if BMAL1 is underexpressed or if there are 
irregularities in BMAL1 availability, but, it has been reported that such mice also exhibit 
premature aging (Bunger et al., 2005; Kondratov et al., 2006; Nadon, 2006). Characteristics of 
progeria, such as disruptions in control of glucose and fat metabolism, homeostasis and 
modulation of genotoxic stress have all been seen in BMAL1 knockout mice (Rudic et al., 2004; 
Shimba et al., 2005).  
Decreased melatonin levels are often found in individuals with depression or related 
psychopathological disorder, like bipolar disorder (Kennedy 1996). In a small sample of US 
individuals with psychopathological disorders, such as bipolar 1 disorder, schizoaffective 
disorder, and schizophrenia, a significant association was found between the reduction in 
BMAL1, Timeless and PER3 concentrations compared to CLOCK (Mansour, 2005). Moreover, 
in a circadian clock gene study that evaluated ten genes, haplotypes in BMAL1 and PER3 were 
assessed to have significant association with bipolar affective disorder (Nievergelt 2006). Hence, 
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it can be said that bipolar disorder is very closely associated with the malfunctioning of the 
circadian rhythm, in part due to abnormal melatonin levels, even at the molecular level. 
The nuclear receptor subfamily 1, group D, member 1 (NR1D1), is the gene for Rev-
ErbA, a protein that regulates cellular proliferation and differentiation that is coupled to the 
circadian rhythm through associations with BMAL1. NR1D1 has been identified as an orphan 
nuclear receptor and is the major regulator of cyclic BMAL1 transcription via the negative 
feedback that is exerted by PER/CRY dimer (Preitner et al., 2002).  More specifically, NR1D1 
has been found to act as a transcriptional inhibitor at the E-box DNA sequence that functions as 
response elements for the core circadian-clock components of CLOCK and BMAL1 
(Triqueneaux et al., 2004). Most importantly, however, it has been determined that NR1D1 
transcription is rhythmic within the hippocampus of rats, primarily due to fluctuations in CRY 
concentration, which is controlled by the BMAL1/CLOCK protein (Valnegri et al., 2011). The 
importance of NR1D1 in development has been seen in the cerebellum of mice lacking the 
NR1D1 gene where unexpected abnormalities including alterations of the Purkinje cell 
development and delays in proliferation and migration of granule cells were observed (Chomez 
et al., 2000). NR1D1 is also a target of interest for drug treatment for certain psychopathological 
disorders. In bipolar disorder, lithium is commonly used to alter the circadian rhythm by 
inhibiting the glycogen synthase kinase 3 (GSK3) which leads to degradation of NR1D1 and 
thereby activation of BMAL1 (Yin et al., 2006). Altered levels of NR1D1 have been seen in 
patients who had disturbed sleep and therefore altered circadian rhythms, which are undoubtedly 
impacted by abnormal levels of melatonin (Wulff et al., 2009). In our study, the lack of 
significant difference in the NR1D1 gene expression observed by alteration of melatonin levels 
in utero seems to indicate that the effects on BMAL1 were not large enough to significantly alter 
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the production of CRY proteins that would then affect NR1D1 expression, or that some other 
component critical to BMAL1 transcriptional regulation is involved. Although clear associations 
between melatonin levels and NR1D1 have not been seen as of yet, alterations in external 
melatonin levels during development will most likely have an effect on fetal development as 
NR1D1 has already been seen to have effects with altered melatonin levels. 
Melatonin and Cognitive Function 
Long-term plasticity has been associated with the activity of the glutamate NMDA 
receptors which are present in high concentration in the hippocampus (Collingridge and Bliss, 
1987; Herron et al., 1986; Bashir et al., 1993).  These metabotropic glutamate receptors have 
been shown to be required for hippocampal long-term potentiation to occur within the 
hippocampus (Malenka and Nicoll, 1993). The NMDA receptor is a heterotetramer made up of 
two GluNR1 and two GluNR2 subunits (either GluNR2A or GluNR2B). In situ hybridization has 
shown that the three subunits are expressed in different concentrations throughout the various 
hippocampal subfields with GRIN1 having the most even expression throughout the 
hippocampus, possibly due to the fact that GRIN1 must be present to form the NMDA 
heterodimer (Xu et al., 2002).  
Studies have also shown that melatonin has different effects on LTP, as melatonin in the 
CA1 region blocked LTP while melatonin injected into the CA3 region barely reduced LTP 
(Ozcan et al., 2006). In relation to melatonin, in a study where melatonin was administered for 
four weeks, concentrations of NMDA receptor subunits 2A and 2B were found to increase within 
the rat hippocampus (Sutcu et al., 2005). Furthermore, melatonin exhibited partial protective 
effects on the NMDA receptor subunits 2A and 2B on rats given ochratoxin A, a mycotoxin that 
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accumulates in the brain and reduces NMDA receptor concentration (Delibas et al., 2003). The 
protective capacity of melatonin was also shown in response to a challenge from quinolinic acid 
degeneration of rat hippocampal neurons (Southgate et al., 1998).  
In contrast to the excitatory effects of glutamate and its NMDA receptors on learning and 
memory, GABA  is the major inhibitory neurotransmitter with its receptor GABAR. There are 
two main classes of GABA receptors - the ionotropic receptor GABAA and the metabotropic 
receptor GABAB; both of the GABAA and GABAB receptors mediate inhibitory postsynaptic 
transmission in the hippocampus (Kuffler and Edwards, 1958; Isaacson et al., 1993). Clinical 
data seems to indicate that psychopathological disorders oftentimes involve decreased GABA 
function where treatments have targeted an upregulation of GABAB receptor (Petty, 1995). 
While there is little data on melatonin’s effect on GABA receptors, a connection between 
melatonin’s ability to control excitability and GABA-containing neurons’ ability to inhibit 
neuronal excitability has been proposed (Golombek et al., 1998; Acufla-Castroviejo et al., 2007). 
Studies have shown that melatonin seems to participate in the regulation of the GABA-
benzodiazepine receptor complex, but does not directly act on the complexes (Nilcs et al., 1987; 
Rosenstein and Cardinali, 1990).  
As previously mentioned, the exact interactions between altered melatonin and behavior 
is scarce, but melatonin has been shown to be correlated with significant differences in pro-
exploratory activity in rats that were tested using a plus-maze (Golombek et al, 1993).  In 
addition, a clinical study reported that melatonin co-administered during withdrawal periods of 
hypnotic drugs have eased the discontinuation (Garfinkel et al., 1999). Moreover, forced 
swimming induced behavioral despair tests have shown similar behavioral response from the rats 
that underwent melatonin treatment and GABA-benzodiazepine receptor agonists (Raghavendra 
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et al., 2000). This suggests that the antidepressant-like effect of melatonin is very similar to the 
effect of GABA-benzodiazepine receptor agonists. If melatonin is having similar inhibitory 
effects on neurons as GABA, this may account for the slight decrease in GABAA and GABAB in 
gene expression, observed in the Melatonin-Noon groups in our study although this data did not 
reach significance. 
 Synaptic plasticity, learning and memory also involve molecules like the neural cell 
adhesion molecule (NCAM), which are members of the immunoglobulin superfamily and are 
expressed on the surface of neuronal cells. Of the three NCAM forms, NCAM140 and 
NCAM180 have shown a decrease in Wistar rats exposed to constant light for 7 days (Baydas et 
al., 2002). In contrast, the rats that were administered melatonin for 7 days had increased levels 
of NCAM140 and NCAM180 expression. Furthermore, injection of 10mg/kg of melatonin, twice 
the amount used compared to our study, into the experimental rats as opposed to the dams 
showed significant alteration in the gene expressions of different NCAM isoforms (Nedzvetsky 
et al., 2003). In our study, altered maternal melatonin levels, on the other hand, do not seem to 
alter NCAM140 expression in the offspring. However, the importance of melatonin was 
supported in our study since the NCAM expression levels in the Luzindole-Noon and Luzindole-
Midnight did not change at all whereas the controls exhibited a significant difference at these 
two time points. These data shows the need for melatonin in the regulation of NCAM expression.  
 The growth-associated protein 43 (GAP43) is another important protein for neural 
plasticity, especially during neuronal development. However, GAP43 has also been seen to play 
critical roles in synaptic remodeling in adults, especially after lesions. Using in situ 
hybridization, an increase in GAP43 mRNA expression was seen in the granule cells of 
hippocampus in rats that underwent experimental lesions (Bendotti et al., 1994). Although there 
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has been no direct study on the effects of melatonin on GAP43 gene expression, studies have 
shown that melatonin has protective effects against neuronal degeneration by maintaining key 
synaptic molecules, such as tyrosine hydroxylase, synaptophysic and GAP43 (Kaewsuk et al., 
2009). Morevoer, alterations in GAP43 have been detected in the brains of individuals with 
psychopathological disorders. In a study on the hippocampi of schizophrenic patients, 
quantitative immunoblots revealed that GAP43 is increased in association cortices as well as in 
the hippocampi, as if it is one manifestation of the brain trying to compensate for the 
perturbations of synaptic organization that schizophrenia is associated with (Perrone-Bizzozero 
et al., 1996; Blennow et al., 1999). This evidence suggested that there might be a connection 
between altered prenatal melatonin and GAP43 expression; however, we did not detect any 
significant differences. 
Circadian Rhythm During Development 
 Our study was designed to examine the importance of the maternal melatonin during fetal 
brain development, in particular, the programming of “set points” for the expression of key genes 
mediating hippocampal control of circadian rhythm. As fetuses are only exposed to their 
mother’s hormone levels while in utero, the maternal circadian circuit becomes the basis for the 
fetal circadian circuit. Hence, when the maternal circadian circuit was disturbed by the presence 
of excess melatonin following its exogenous administration, or, suppression of melatonin 
following the administration of luzindole, a significant change was observed in the offspring’s 
expression of BMAL1, one of the key clock genes that control the circadian cycle. It is important 
to note, however, that the altered levels of melatonin and consequent changes in hippocampal 
BMAL1 gene expression did not have any significant effects on the expression of other genes 
that have been reported to be changed by alteration in melatonin or circadian rhythm 
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disturbances, including those for subunits of NMDA receptors as well as GABA receptors. This 
could suggest that there are protective mechanisms in the mother or fetus that override the 
influence of the particular dose of melatonin and luzinolde that were used in our study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52  
REFERENCES 
 
Acufla-Castroviejo D, Escames G, Macks M, Hoyos AM, Carballo AM, Arauzo M,  
Montes R, Vives F. 2007. Minireview: Cell protective role of melatonin in brain. Journal 
of Pineal Research 19(2):57-6. 
Amrein I, Lipp HP. 2009. Adult hippocampal neurogenesis of mammals: Evolution and l 
ife history. Biology Letters 4:141-144.  
Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM,  
Vinogradova IA. 2006. Melatonin as antioxidant, neuroprotector and anticarcinogen. 
Biochimica et Biophysica Acta 1757:573-589. 
Arendt J. 1998. Melatonin and the pineal gland: influence on mammalian seasonal and  
circadian physiology. Reviews of Reproduction 3:13-22. 
Bannerman DM, Rawlins JNP, McHugh SB, Deacon RMJ, Yee BK, Bast T, Zhang WN,  
Pothuizen HHJ, Feldo J. 2004. Regional dissociations within the hippocampus – memory 
and anxiety. Neuroscience and Biobehavioral Reviews 28:273-283. 
Bashir ZI, Bortolotto ZA, Davies CH, Berretta N, Irving AJ, Seal AJ, Henley JM, Jane  
DE, Watkins JC, Collingridge GL. 1993. Induction of LTP in the hippocampus needs 
synaptic activation of glutamate metabotropic receptors. Nature 363:347-350. 
Baydas G, Nedzvetsky VS, Nerush PA, Kirichenko SV, Demchenko HM, Reiter RJ.  
2002. A novel role for melatonin: regulation of the expression of cell adhesion molecules 
in the rat hippocampus and cortex. Neuroscience Letters 326:209-112. 
Bendotti C, Pende M, Samanin R. 1994. Expression of GAP-43 in the granule cells of rat  
hippocampus after seizure-induced sprouting of mossy fibres: in situ hybridization and 
immunocytochemical studies. European Journal of Neuroscience 6(4):509-515. 
Berra B, Rizzo AM. 2009. Melatonin: circadian rhythm regulator, chronobiotic,  
antioxidant and beyond. Clinics in Dermatology 27:202-209. 
Blennow K, Bogdanovic N, Gottfries CG, Davidsson P. 1999. The growth-associated  
protein GAP-43 is increased in the hippocampus and in the gyrus cinguli in 
schizophrenia. Journal of Molecular Neuroscience 13 (1-2):101-109. 
Bunger MK, Wilsbacher LD, Moran SM, Clendenin C, Radcliffe LA, Hogenesch JB,  
Simon MC, Takahashi JS, Bradfield CA. 2000. Mop3 is an essential component of 
master circadian pacemaker in mammals. Cell 120:513-522. 
Bunger MK., Walisser JA., Sullivan R, Manley PA, Moran SM, Kalscheur VL,  
Colman RJ, Bradfield CA. 2005. Progressive arthropathy in mice with a target  disruption 
of the Mop3/Bmal1 locus. Genesis 41:122-132. 
Cagnacci A, Elliot JA, Yen SS. 1992. Melatonin: a major regulator of the circadian  
rhythm of core temperature in humans. Journal of Clinical Endocrinology and 
Metabolism 75(2):447. 
Cardinali DP, Pevet P. 1998. Basic aspects of melatonin action. Sleep Medicine  
Reviews. 2(3): 175-190. 
Chomez P, Neveu I, Mansen A, Kiesler E, Larsson L, Vennstrom B, Arenas E. 2000.  
Increased cell death and delayed development in the cerebellum of mice lacking the rev-
erb A (alpha) orphan receptor. Development 127(7):1489-1498. 
Claustrat B, Brun J, Chazot G.  2005. The basic physiology and pathophysiology of  
melatonin. Sleep Medicine Reviews 9:11-24. 
Collingridge G, Bliss TV. 1987. NMDA receptors: Their role in long-term potentiation.  
53  
Trends in Neurosciences 10(7):288-293. 
Dardente H, Menet JS, Poirel VJ, Streicher D, Gauer F, Vivien-Roels B, Klosen P, Pevet  
P, Masson-Pevet M. 2003. Melatonin induces Cry1 expression in the pars tuberlalis of the 
rat. Molecular Brain Research. 114(2):101-106. 
Delibas N, Altuntas I, Yonden Z, Ozcelik N. 2003. Ochratoxin A reduces NMDA  
receptor subunits 2A and 2B concentrations in rat hippocampus: partial protective effect 
of melatonin. Human & Experimental Toxiclogy 22:335-339. 
Dellaspezia S. 2009. Melatonin, circadian rhythms, and the clock genes in bipolar  
disorder. Psychiatry Reports 11:488-493. 
Dubocovich ML. 1988. Luzindole (N-0774): A novel melatonin receptor antagonist. The  
Journal of Pharmacology and Experimental Therapeutics 246(3):902-910. 
Drake CL. 2010. The characterization and pathology of circadian rhythm sleep  
disorders. Journal of Family Practice 59:S12-S17. 
Ebihara S, Marks T, Hudson DJ, Menaker M. 1986. Genetic control of melaonin  
synthesis in the pineal gland of the mouse. Science 231:491-493. 
El-sherif Y, Tesoriero J, Hogan MV, Wieraszko A. 2003. Melatonin regulates neuronal  
plasticity in the hippocampus. Journal of Neuroscience Research 72(4):454-460. 
Escames G, Leon J, Lopez LC, Acuna Castroviejo D. 2004. Mechanisms of N-methyl0D- 
Aspartate Receptor inhibition by melatonin in the rat striatum. Journal of 
Neuroendocrinology 16(11):929-935. 
Garfinkel D, Zisapel N, Wainstein J, Laudon M. 1999. Facilitation of benzodiazepine  
discontinuation by melatonin: a new clinical approach. Archives of Internal Medicine 
159:2456-2460. 
Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP, Takahashi JS,  
Weitz CJ. 1998. Role of the CLOCK protein in the mammalian circadian mechanism. 
Science 280:1564-1569. 
Golombek DA, Martini M, Cardinali DP. 1993. Melatonin as an anxiolytic in rats: time  
dependence and interaction with the central GABAergic system. European Journal of 
Pharmacology 237:231-236. 
Golombek DA, Pevet P, Cardinali DP. 1996. Melatonin effects on behavior: possible  
mediation by the central GABAergic system. Neuroscience & Behavioral Reviews 
20(3):403-412. 
Hardeland R. 2005. Antioxidative protection by melatonin: Multiplicity of mechanisms  
from radical detoxification to radical avoidance. Endocrine 27(2):119-130 
Hardeland R, Pandi-Perumal SR, Cardinali DP. 2006. Melatonin. International  
Journal of Biochemistry and Cell Biology 38:313-316. 
Harrison PJ. 2004. The hippocampus in schizophrenia: a review of the neuropathological  
evidence and its pathophysiological implications. Psychopharmacology 174:151- 
162. 
Heid CA, Stevens J, Livak KJ, Williams PM. 1996. Real Time Quantitative PCR.  
Genome Methods 6:986-994. 
Herrington JD, Heller W, Mohanty A, Engels AS, Banich MT, Webb AG, Miller GA.  
2010. Localization of asymmetric brain function in emotion and depression. 
Psychophysiology 47:442-454. 
Herron CE, Lester RAJ, Coan EJ, Collingridge GL. 1986. Frequency-dependent  
54  
involvement of NMDA receptors in the hippocampus: a novel synaptic mechanism. 
Nature 322:365-268. 
Hirsch-Rodriguez E, Imbesi M, Manev R, Uz T, Manev H. 2007. The pattern of  
melatonin receptor expression in the brain may influence antidepressant treatment. 
Medical Hypotheses 69(1):120-124. 
Isaacson JS, Solis JM, Nicoll RA. 1993. Local and diffuse synaptic action for GABA in  
the hippocampus. Neuron 10(2): 166-175. 
Jolley SN, Elmore S, Barnard KE, Carr DB. 2007. Dysregulation of the hypothalamic- 
pituatary-adrenal axis in postpartum depression. Biological Research for Nursing 8(3): 
210-222. 
Kaewsuk S, Sae-ung K, Phansuwan-Pujito P, Govitrapong P. 2009. Melatonin attenuates  
methamphetamine-induced reduction of tyrosine hydroxylase, synaptophysin and growth-
associated protein-43 levels in the neonatal rat brain. Neurochemistry International 
55:397-405. 
Kalsbeek A, Drijfhout WJ, Westerink BHC, van Heerikhuize JJ, van de Woude TP, van  
der Vliet J, Bujis RM. 1996. GABA receptors in the region of the dorsomedial 
hypothalamus of rats are implicated in the control of melatonin and corticosterone 
release. Neuroendocrinology 63(1):69-78. 
Kennedy SH, Kutcher SP, Ralevski E, Brown GM. 1996. Nocturnal melatonin and 24- 
hour 6-sulphatoxymelatonin levels in various phases of biplar affective disorder. 
Psychiatry Research 63:219-222. 
Kennedy SH, Garfinkel PE, Parienti V, Costa D, Brown GM. 1989. Changes in  
melatonin levels but not cortisol levels are associated with depression in patients with 
eating disorders. Archives of General Psychiatry 46(1):73-78. 
KnableMB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF. 2004. Molecular  
abnormalities of the hippocampus in severe psychiatric illness: Postmortem finding from 
the Stanley Neuropathology Consortium. Molecular Psychiatry 9:609:620. 
Kondratov RV, Kondratova AA, Lee C, Gorbacheva VY, Vykhovanets OV, Antoch MP.  
2006. Early aging and age-related pathologies in mice deficient in BMAL1, the core 
component of the circadian clock. Genes Development 20:1868-1873. 
Koch BCP, Nagtegaal E, Kerkhof GA, ter Wee PM. 2009. Circadian sleep-wake rhythm  
disturbances in end-stage renal disease. Nature Reviews Nephrology 5:407-416. 
Koch BCP, Nagtegaal JE, Hagen EC, ter Wee PM, Kerkhof GA. 2009. Different  
melatonin rhythms and sleep-wake rhythms in patients on peritoneal dialysis, daytime 
hemodialysis and nocturnal hemodialysis. Sleep Medicine 11(3):242-246. 
Kondratov RV. 2007. A role of the circadian system and circadian proteins in aging. 
Aging Research Reviews 6:12-27. 
Kripke DF, Nievergelt CM, Joo EJ, Shekhtman T, Kelsoe JR. 2009. Circadian  
polymorphisms associated with affective disorders. Journal of Circadian Rhythms 7(2): 
1-10. 
Kuffler SW, Edwards C. 1958. Mechanism of gamma aminobutyric acid (GABA) action  
and its relation to synaptic inhibition. Journal of Neurophysiology 21:581-610. 
Lapin LP, Mirzaev SM, Ryzov IV, Oxenkrug GF. 2007. Anticonvulsant activity of melatonin  
against seizures induced by quinolinate, kinate, glutamate, NMDA, and 
pentylenetetrazole in mice. Journal of Pineal Research 24(4):215-218. 
Larson J, Jessen RE, Uz T, Arslan AD, Kurtuncu M, Imbesi M, Manev H. 2005.  
55  
Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. 
Neuroscience Letters 393(1):23-26. 
Layeghifard M, Rabani R, Pirhaji L, Yakhchali B. 2008. Evolutionary mechanisms  
underlying the functional divergence of duplicate genes involved in vertebrates’ circadian 
rhythm pathway. Gene 426(1-2):65-71. 
Leibenluft E, Feldman-Naim S, Turner EH, Wehr TA, Rosenthal NE. 1997. Effects of  
exogenous melatonin administration and withdrawal in five patients with rapid-cycling 
bipolar disorder. The Journal of Clinical Psychiatry 58(9):383-388. 
Lima ACP, Louzado PR, De Mello FG, Ferreira ST. 2003. Neuroprotection against AB and  
glutamate toxicity by melatonin: Are GABA receptors involved? Neurotoxicity Research 
5(5): 323-328. 
Liu C, Reppert SM. 2000. GABA synchronizes clock cells within the Suprachiasmatic  
circadian clock. Neuron 25(1):123-128. 
Liu HX, Zhang JJ, Zheng P, Zhang Y. 2005. Altered expression of MAP-2, GAP-43, and  
synaptophysin in the hippocampus of rats with chronic cerebral hypoperfusion correlated 
with cognitive impairment. Molecular Brain Research 139:169-177. 
Malenka RC and Nicoll RA. 1993. NMDA-receptor-dependent synaptic plasticity:  
Multiple forms and mechanisms. Trends in Neurosciences 16(12): 521-527. 
Mandera M, Dec R, Marcol W, Kotulska K. 2003. Melatonin secretion profile after  
experimental pineal gland compression in rats. Neuroendocrinology Letters 6(24): 392-
396. 
Mansour HA, Wood J, Logue T, Chowdari KV, Dayal M, Kupfer DJ, Monk TH, Devlin  
B, Nimgaonkar VL. 2005. Association study of eight circadian genes with bipolar I 
disorder, schizoaffective disorder and schizophrenia. Genes, Brain and Behavior 5(2): 
150-157. 
Melke J, Goubron Botros H, Chaste P, Betancur C, Nygren G, Ankarsater H, Rastam M,  
Stahlberg O, Gilber IC, Delorme R, Chabane N, Mouren Simeoni M-C, Fauchereau F, 
Durand CM, Chevalier F, Drouot X, Collet C, Launay J-M, Lebyoer M, Gillberg C, 
Bourgeron T. 2008. Abnormal melatonin synthesis in autism spectrum disorders. 
Molecular Psychiatry 13:90-98. 
Moriya T, Horie N, Mitome M, Shinohara K. 2007. Melatonin influences the  
proliferative and differentiative activity of neural stem cells. Journal of Pineal Research 
42:411-418. 
Musshoff U, Riewenherm D, Berger E, Fauteck JD, Speckmann EJ. 2002. Melatonin  
receptors in rat hippocampus: molecular and functional investigations. Hippocampus 12: 
165-173. 
Nadon NL. 2006. Exploiting the rodent model for studies on the pharmacology of  
lifespan extension. Aging Cell 5:9-15. 
Nedzvetsky VS, Nerush PA, Kirichenko SV. 2003. Effects of melatonin on behavioral  
reactions and on the expression of NCAM in rats. Neurophysiology 35(2):102-107. 
Nilcs LP, Pickering DS, Arciszewski MA. 1987. Effects of chronic melatonin  
administration on GABA and diazepam binding in rat brain. Journal of Neural 
Transmission 70(1-2):117-124. 
Nievergelt CM, Kripke DF, Barrett TB, Burg E, Remick RA, Sadovnick AD, McElroy  
56  
SL, Keck PE, Schork NJ, Kelsoe JR. 2006. Suggestive evidence for association of the 
circadian genes PERIOD3 and ARNTL with bipolar disorder. American Journal of 
Medical Genetics Part B (Neuropsychiatric Genetics) 141B:234-241. 
Novakova M, Polidarova L, Sladek M, Sumova A. 2011. Restricted Feeding Regime  
Affects clock gene expression profiles in the suprachiasmatic nucleus of rats posed to 
constant light. Neuroscience 197:65-71. 
Okamura H, Yamaguchi S, Yagita K. 2002. Molecular machinery of the circadian clock  
in mammals. Cells and Tissue Research 309(1):47-56. 
Ozcan M, Yilmaz B, Carpenter DO. 2006. Effects of melatonin on synaptic transmission  
and long-term potentiation in two areas of mouse hippocampus. Brain Research 
1111(1):90-94. 
Petty F. 1995. GABA and mood disorders: a brief review and hypothesis. Journal of  
Affective Disorders 34(4)275-281. 
Perrone-Bizzozero NI, Sower AC, Bird ED, Benowitz LI, Ivins KJ, Neve RL. 1996.  
Levels of the growth-associated protein GAP-43 are selectively increased in association 
cortices in schizophrenia. Procedures for the National Academy of Science 93:14182-
14187. 
Preitner N, Damiola F, Lopez-Molina L, Zakany J, Duboule D, Albrecht U, Schibler U.  
2002. The orphan nuclear receptor REV-ERBa controls circadian transcription within the 
positive limb of the mammalian circadian oscillator. Cell 110(2):251-260. 
Raghavendra V, Kaur G, Kulkami S. 2000. Anti-depressant action of melatonin in  
chronic forced swimming-induced behavioral despair in mice, role of peripheral 
benzodiazepine receptor modulation. European Neuropsychopharmacology 10(6):473-
481. 
Ramirez-Rodriguez G, Klempin F, Babu H, Benitez-King G, Kempermann G. 2009.  
Melatonin modulates cell survival of new neurons in the hippocampus of adult mice. 
Neuropsychopharmacology 34:2180-2191. 
Rao ML, Gross G, Strebel B, Halaris A, Huber G, Braunig P, Marler M. 1994. Circadian  
rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. 
Societ of Biological Psychiatry 35:151-163. 
Richter HG, Torres-Farfan C, Rojas-Garcia PP, Campino C, Torrealba F, Seron-Ferre  
M. 2004. The circadian timing systems: making sense of day/night gene expression. 
Biological Research 37:11-28. 
Ripple J. 2010. The effects of altered prenatal melatonin signaling on adult behavior and  
hippocampal gene expression of the male rat: A circadioneuroendocrine-axis hypothesis 
of psychopathology. Bucknell University Honor’s Thesis in Neuroscience. 
Rojas RJ, Dalvi A. 1997. Anxiety, defence and the elevated plus-maze. Neuroscience and  
Biobehavioral Reviews 21(6):801-810. 
Rosenstein RE, Cardinali DP. 1986. Melatonin increases in vivo GABA accumulation in rat  
hypothalamus, cerebellum, cerebral cortex and pineal gland. Brain Research 398(2):403-
406. 
Rosenstein RE, Cardinali DP. 1990. Central GABAergic mechanisms as targets for  
melatonin activity in brain. Neurochemistry International. 17(3):373-379. 
Rudic RD, McNamara P, Curtis AM, Boston RC, Panda S, Hogenesch JB, Fitgerald GA.  
2004. BMAL1 and CLOCK, two essential components of the circadian clock, are 
involved in glucose homeostasis. Public Library of Science Biology 2:e377. 
57  
Sack RL, Lewy AJ, Hughes RJ. 1998. Use of melatonin for sleep and circadian rhythm  
disorders. Annals of Medicine 30(1):115-121. 
Saitoh O, Karns CM, courchesne E. 2001. Development of the hippocampal formation  
from 2 to4 2 years:MRI evidence of smaller area dentate in autism. Brain 124:1317-1324. 
Sandyk R, Kay SR. 1990. Pineal melatonin in schizophrenia: A review and hypothesis.  
Schizophrenia Bulletin 16(4):653-662. 
Sangoram AM, Saez L, Antoch MP, Gekakis N, Staknis D, Whiteley A, Fruechte EM,  
Vitaterna MH, Shimomura K, King DP, Young MW, Weitz CJ, Takahashi JS. 1998. 
Mammalian circadian autoregulatory loop: a Timeless ortholog and mPer1 interact and 
negatively regulate CLOCK-BMAL1-induced transcription.  Neuron 21:1101-1113. 
Savaskan E, Ayoub MA, Ravid R, Angeloni D, Fraschini F, Meier F, Eckert A, Muller- 
Spahn F, Jockers R. 2005. Reduced hippocampal MT2 melatonin receptor expression in 
Alzheimer’s disease. Journal of Pineal Research 38(1):10-16. 
Savaskan E, Olivieri G, Brydon L, Jockers R, Krauchi K, Wirz-Justice A, Muller0Spahn  
F. 2001. Cerebrovascular melatonin MT1-receptor alterations in patients with 
Alzheimer’s disease. Neuroscience Letters 308(1):9-12. 
Schwartz PJ. 2011. Season of birth in schizophrenia: A maternal-fetal chronobiological  
hypothesis. Medical Hypotheses 76(6): 785-793. 
Scoville WB, Milner B. 1957. Loss of recent memory after bilateral hippocampal lesions.  
Journal of Neurology, Neurosurgery and Psychiatry 20(11):11-21. 
Shearman LP, Sriram S, Weaver DR, Maywood ES, Chaves I, Zheng B, Kume K, Lee  
CC, van der Horst GTJ, Hastings MH, Reppert SM. 2000. Interacting molecular loops in 
the mammalian circadian clock. Science 288:1013-1019. 
Shimba S, Ishii N, Ohta Y, Ohno T, Watabe Y, Hayashi M, Wada T, Aoyagi T, Tezuka  
M. 2005. Brain and muscle Arnt-like Protein-1 (BMAL1), a component of the molecular 
clock, regulates adipogensis. Proceedings of the National Academy of Sciences of the 
United States. 102:12071-12076. 
Simmonneaux V, Ribelayga C. 2003. Generation of the melatonin endocrine message  
in mammals: a review of the complex regulation of melatonin synthesis by 
norepinephrine, peptides, and other pineal transmitters. Pharmacological Reviews 55(2): 
325-395. 
Souetre E, Salavati E, Belugou JL, Pringuey D, Candito M, Krebs B, Ardisson JL,  
Darcourt G. 1988. Circadian rhythms in depression and recovery: eveidence for blunte 
amplitude as the main chronobiological abnormality. Psychiatry Research 28:263-278. 
Southgate GS, Daya S, Potgieter B. 1998. Melatonin plays a protective role in quinolinic  
acid-induced neurotoxicity in the rat hippocampus. Journal of Chemical Neuroanatomy 
14(3-4): 151-156. 
Srinivasan V, Smits M, Spence W, Lowe AD, Kayumov L, Pandi-Perumal SR, Parry B,  
Cardinali DP. 2006. Melatonin in mood disorders. Journal of Biological Psychiatry 
7(3):138-151. 
Stetson MH, Sarafidis E, Rollag MD. 1986. Sensitivity of adult male Djungarian  
hamsters (Phodopus sungorus sungorus) to melatonin injections throughout the day: 
effects on the reproductive system and the pineal. Biology of Reproduction 35(3):618-
623. 
Sukumaran S, Almon RR, DuBois DC, Jusko WJ. 2010. Circadian rhythms in gene  
58  
expression: Relationship to physiology, disease, drug disposition and drug action. 
Advanced Drug Delivery Reviews 62(9-10): 904-917. 
Sumaya IC, Masana MI, Dubocovich ML. 2005. The antidepressant-like effect of the  
melatonin receptor ligand luzindole in mice during forced swimming required expression 
of MT2 but not MT1 melatonin receptors. Journal of Pineal Research 39:170-177. 
Sutcu R, Yonden Z, Imaz AY, Delibas N. 2005. Melatonin increases NMDA receptor  
subunits 2A and 2B concentrations in rat hippocampus. Molecular and Cellular 
Biochemistry 283(1-2):101-105. 
Tamura H, Nakamura Y, Terron MP, Flores LJ, Manchester LC, Tan DX, Sugino N,  
Reiter RJ. 2008. Melatonin and pregnancy in the human. Reproductive Toxicology 
25(3):291-303. 
Tang AC, Reeb BC, Romeo RD, McEwen BS. 2003. Modification of social memory,  
hypothalamic-pituatary-adrenal axis, and brain asymmetry by neonatal novelty exposure. 
The Journal of Neuroscience. 23(23):8254-8260. 
Tang PL, Pang SF. 1988. The ontogeny of pineal and serum melatonin in male rats at  
mid-light and mid-dark. Journal of Neuronal Transmission 72(1):43-53. 
Torres-Farfan C, Rocco V, Monso F, Valenzuela FJ, Campino C, Germain A, Torrealba  
F, Valenzuela GJ, Seron-Ferre M. 2006. Maternal melatonin effects on clock gene 
expression in a nonhuman primate fetus. Neuroendocrinology 147(10):4618-4626. 
Torrey EF, Miller J, Rawlings R, Yolken RH. 1997. Seasonlity of births in schizophrenia  
and bipolar disorder: a review of the literature. Schizophrenia Research 28:1-38. 
Triqueneaux G, Thenot S, Kakizawa T, Antoch MP, Safi R, Takahashi JS, Delaunay F,  
Laudet V. 2004. The orphan receptor Rev-ErbA gene is a target of the circadian clock 
pacemaker. Journal of Molecular Endocrinology 33:585-608. 
Turgut M, Uyankgil Y, Baka N, Yurtseven M. 2006. Pinealectomy stimulates and  
exongenous melatonin inhibits harmful effects of epileptiform activity during pregnancy 
in the hippocampus of newborn rats: an immunohistochemical study. Child’s Nervous 
System 22: 481-488. 
Uz T, Giusti P, Franceschini D, Kharlamov A, Manev H. 1996. Protective effect of melatonin  
against hippocampal dna damage induced by intraperitoneal administration of kainite to 
rats. Neuroscience 73(3):631-636. 
Valnegri P, Khelfaoui M, Dorseuil O, Bassani S, Lagneaux C, Gianfelice A, Benfante R,  
Chelly J, Billuart P, Sala C, Passafaro M. 2011. A circadian clock in hippocampus is 
regulated by interaction between oligophrenin-1 and Rev-erbA. Nature Neuroscience 
14:1293-1391. 
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F.  
2002. Accurate normalization of real-time quantitative RT-PCRdata by geometric 
averaging of multiple internal control genes. Genome Biology 3(7) 1-12. 
Von Gall C, Weaver DR, Moek J, Jilg A, Stehle JH, Korf H-W. 2005. Melatonin plays a  
crucial role in the regulation of rhythmic clock gene expression in the mouse pars 
tuberalis. Annals of New York Academy of Sciences, 1040:508-511.  
Vrajova M, Stastny F, Horacek J, Lochman J, Sery O, Pekova S, Klaschka J, Hoschl C.  
2010. Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing 
isoforms in schizophrenia: postmortem study. Neurochemical Research 35(7):994-1002. 
Wang LM, Suthana NA, Chaudhury D, Weaver DR, Colwell CS. 2005. Melatonin  
59  
inhibits hippocampal long-term potentiation. European Journal of Neuroscience 
22(9):2231-2237. 
Wasserf A, Baker J, Kochan LD. GABA and schizophrenia: a review of basic science  
and clinical studies. Journal of Clinical Psychopharmacology 23(6):601-640. 
Weisen MP, Hanlon FM, Yeo RA, Huang M, Roland RL, Thoma RJ, Moses SN, Paulson  
KM, Miller GA, Canive JM. 2005. A specific test of hippocampal deficit in 
schizophrenia. Behavioral Neuroscience 119(4):863-875. 
Wilkinson IR, Ferrandis E, Artymiuk PJ, Teillot M, Soulard C, Touvay C, Pradhananga  
SL, Justice S, Wu Z, Leung KC, Strasburger CJ, Sayers JR, Ross RJ. 2007. A ligand-
receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist. 
Nature Medicine 13(9):1108-1113. 
Wulff K, Porcheret K, Cussans E, Foster RG. 2009. Sleep and circadian rhythm  
disturbances: multiple genes and multiple phenotypes. Current Opinion in Genetics and 
Development 19(3):237-246. 
Xu TJ, Liu Z, Wang Y. 2002. The expression of mRNA of NMDA receptor subunits  
NR1, NR2A and NR2B in the hippocampus of adult rat. Acta Academiae Medicinae 
Xuzhou. 
Yamaguchi S, Isejima H, Matsuo T, Okura R, Yagita K, Kobayashi M, Okamura H.  
2003. Synchronization of cellular clocks in the suprachiasmatic nucleus. Science 
302(5649): 1408-1412. 
Yin L, Wang J, Klein PS, Lazar MA. 2006. Nuclear receptor Rev-ErbA is a critical  
lithium-sensitive component of the circadian clock. Science 311(5763):1002-1005. 
Zhdanova IV, Tucci V. 2003. Melatonin, circadian rhythms, and sleep. Current  
Treatment Options in Neurology. 5(3):225-229. 
Zitouini M, Masson-Pevet M, Gauer F, Pevet P. 1995. Influence of maternal melatonin  
on melatonin receptors in rat offspring. Journal of Neural Transmission 100:111-122. 
 
